International Journal of Pharmaceutical Investigation, 2023, 13, 2, 359-366.
DOI: 10.5530/ijpi.13.2.046
Published: March 2023
Type: Original Article
Authors:
Ruhul Amin
Faculty of Pharmaceutical Science, Assam Down Town University, Panikhaiti, Guwahati, Assam, INDIA.
Biplab Kumar Dey
Faculty of Pharmaceutical Science, Assam Down Town University, Panikhaiti, Guwahati, Assam, INDIA.
Faruk Alam
Faculty of Pharmaceutical Science, Assam Down Town University, Panikhaiti, Guwahati, Assam, INDIA.
ABSTRACT
Objectives: The objective of this study was to develop Chronic Kidney Disease Patient Information Leaflets (CKD-PILs) to test their understandability and assess their usefulness. Materials and Methods: Prospective observational research was carried out in a dialysis unit at renowned medical care for 9 months and 140 CKD patients enrolled in the study to evaluate prepared CKD-PILs. Patient Information Leaflets (PILs) is prepared by referring to various medical database and it’s evaluated using computer-aided readability tools using the website “http://r eadabilityscore.com”. Afterward, PIL was translated into a regional language and verified by a subject expert. The design and layout were analyzed using BADL criteria and user option tests. Results: Prepared CKD-PILs found to be good design and layout as per BALD and user opinion (BALD Assamese: 27, BALD English: 28; User opinion: 82.7% for Assamese PILs and 89.2% for English PILs). The mean scores on the knowledge evaluated using user testing methods and Disease management and lifestyle-related knowledge increased from 49.08±4.16 to 80.40±5.71 (p<0.001) and is statistically significant. Conclusion: The results showed significant improvement of their lifestyle and disease-related knowledge after the implementation of PILs. The Prepared CKD-based patient information leaflets have been found to be a good and effective educational tool for CKD patients.
Keywords: Pharmaceutical care, Patient Information Leaflets (PILs), Hemodialysis (HD), Chronic kidney disease, BALD, CKD-PILs.